• LAST PRICE
    4.8600
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    4.6900/ 2
  • Ask / Lots
    4.9800/ 4
  • Open / Previous Close
    --- / 4.8600
  • Day Range
    ---
  • 52 Week Range
    Low 0.7200
    High 6.1856
  • Volume
    62
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 4.91
TimeVolumeRZLT
09:32 ET26714.93
09:33 ET1004.93
09:35 ET5004.95
09:37 ET50004.935
09:39 ET51004.9415
09:42 ET68414.97
09:44 ET62474.97
09:46 ET25004.93
09:48 ET53354.94
09:50 ET26504.96
09:51 ET34294.9595
09:53 ET16004.98
09:55 ET14004.97
09:57 ET7384.95
10:00 ET2004.94
10:02 ET33574.915
10:04 ET1004.92
10:06 ET13004.9
10:08 ET29744.91
10:11 ET25104.95
10:13 ET25274.92
10:15 ET35284.9
10:18 ET10254.94
10:20 ET5004.92
10:22 ET6004.93
10:24 ET1004.92
10:26 ET1004.925
10:27 ET3004.93
10:33 ET1004.94
10:36 ET7004.94
10:38 ET1074.93
10:40 ET2004.93
10:42 ET3164.945
10:45 ET4004.96
10:47 ET1004.97
10:49 ET9324.975
10:51 ET8004.975
10:54 ET8004.97
10:58 ET16004.96
11:00 ET2504.955
11:02 ET7004.96
11:03 ET20004.97
11:05 ET3004.97
11:07 ET1524.96
11:12 ET2004.94
11:14 ET1004.94
11:16 ET1004.94
11:20 ET17284.94
11:21 ET9334.915
11:25 ET4004.915
11:27 ET2564.9055
11:30 ET3004.94
11:32 ET1004.9
11:36 ET11034.92
11:38 ET1004.92
11:39 ET4004.91
11:43 ET1004.9
11:45 ET1004.91
11:48 ET3364.93
11:52 ET56004.94
11:56 ET1004.95
11:59 ET72314.97
12:01 ET2004.98
12:03 ET11004.97
12:06 ET1004.98
12:10 ET17364.975
12:12 ET8004.96
12:14 ET2004.95
12:15 ET4004.95
12:17 ET2004.95
12:21 ET8004.94
12:24 ET5004.945
12:30 ET6004.93
12:32 ET4994.94
12:33 ET52524.945
12:39 ET6004.945
12:42 ET6004.95
12:46 ET1004.94
12:48 ET58304.95
12:51 ET5004.941
12:53 ET5004.94
12:55 ET1004.94
12:57 ET1004.945
01:00 ET3004.9449
01:02 ET31754.95
01:04 ET1004.96
01:06 ET38924.96
01:15 ET11334.965
01:18 ET9004.97
01:20 ET11004.96
01:22 ET4504.955
01:24 ET2004.96
01:26 ET18464.95
01:27 ET5784.9488
01:29 ET4004.945
01:31 ET2004.94
01:33 ET2004.94
01:36 ET5004.9486
01:42 ET2004.94
01:44 ET8004.93
01:45 ET12004.92
01:47 ET2154.92
01:51 ET18604.93
01:56 ET18224.9
01:58 ET6754.9
02:02 ET6094.89
02:03 ET7464.91
02:07 ET8004.94
02:09 ET1004.92
02:14 ET7384.93
02:16 ET7004.93
02:18 ET3164.93
02:20 ET8014.91
02:21 ET3004.92
02:23 ET5004.91
02:27 ET1004.9
02:30 ET2004.9181
02:32 ET2004.92
02:38 ET13004.91
02:48 ET5004.925
02:50 ET1004.92
02:52 ET44494.905
02:54 ET1004.905
02:56 ET14904.89
02:57 ET3004.9
02:59 ET84574.87
03:01 ET1004.88
03:03 ET3004.88
03:06 ET13004.87
03:08 ET5004.86
03:10 ET1004.86
03:12 ET2004.87
03:14 ET9334.87
03:15 ET1004.86
03:17 ET3004.862
03:19 ET3004.88
03:21 ET11914.87
03:24 ET3004.88
03:26 ET1004.88
03:28 ET2004.88
03:30 ET1004.88
03:32 ET15114.9
03:33 ET4004.91
03:37 ET2004.89
03:39 ET15004.89
03:42 ET1424.89
03:44 ET10004.89
03:46 ET3004.88
03:48 ET2264.88
03:50 ET11594.9
03:51 ET8004.88
03:53 ET6454.885
03:55 ET16924.875
03:57 ET12884.88
04:00 ET386894.86
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRZLT
Rezolute Inc
284.5M
-3.8x
---
United StatesAVIR
Atea Pharmaceuticals Inc
284.6M
-1.6x
---
United StatesALDX
Aldeyra Therapeutics Inc
288.8M
-6.6x
---
United StatesATAI
ATAI Life Sciences NV
270.2M
-2.1x
---
United StatesNAUT
Nautilus Biotechnology Inc
301.4M
-4.3x
---
United StatesNGNE
Neurogene Inc
301.6M
-5.0x
---
As of 2024-11-26

Company Information

Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.

Contact Information

Headquarters
275 Shoreline Drive, Suite 500REDWOOD CITY, CA, United States 94065
Phone
650-206-4507
Fax
302-636-5454

Executives

Acting Chairman of the Board, Chief Executive Officer
Nevan Elam
Chief Financial Officer
Daron Evans
Chief Medical Officer
Brian Roberts
Director
Young-Jin Kim
Independent Director
Philippe Fauchet

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$284.5M
Revenue (TTM)
$0.00
Shares Outstanding
57.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.02
EPS
$-1.27
Book Value
$2.27
P/E Ratio
-3.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.